From: Patient involvement to inform the design of a clinical trial in postbariatric hypoglycaemia
Characteristic | Median (IQR; range) | n (%) |
---|---|---|
Total | 29 (100%) | |
Age | 40.45 (IQR 31–51.5; 20–57) | |
Sex | ||
male | 2 (6.9%) | |
female | 17 (58.6%) | |
no response | 10 (34.4%) | |
Type of surgery | ||
Roux-Y gastric bypass | 18 (62.1%) | |
sleeve gastrectomy | 1 (3.4%) | |
others | 1 (3.4%) | |
no response | 9 (31.0%) | |
Duration since bariatric surgery (years) | 5 (IQR 2.8–7; range 1–9) | |
Number of hypoglycemic episodes per week | ||
daily | 5 (17.2%) | |
not daily, but several days a week | 10 (34.5%) | |
not weekly, but at least once a month | 5 (17.2%) | |
no response | 9 (31.0%) | |
Patients receiving off-label drug therapy | ||
yes | 9 (31.0%) | |
no | 11 (37.9%) | |
no response | 9 (31.0%) | |
Type of off-label therapy for postbariatric hypoglycemia | ||
acarbose | 2 | |
liraglutide | 2 | |
empagliflozin | 2 | |
octreotide | 1 | |
onglyza | 1 |